; 812)— (1) review the relevant data pertaining to the scheduling of products containing a combination of buprenorphine and naloxone that have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ); and (2) if appropriate, request that the Attorney General initiate rulemaking proceedings to revise the schedules accordingly with respect to such products. (b) Attorney General The Attorney General shall review any request made by the Secretary of Health and Human Services under subsection (a)(2) and determine whether to initiate proceedings to revise the schedules in accordance with the criteria set forth in sections 201 and 202 of the Controlled Substances Act ( 21 U.S.C. 811 ; 812). 203. Combating illicit xylazine (a) Definitions (1) In general In this section, the term xylazine has the meaning given the term in paragraph (60) of section 102 of the Controlled Substances Act, as added by paragraph (2). (2) Controlled Substances Act Section 102 of the Controlled Substances Act ( 21 U.S.C. 802 ) is amended— (A) by redesignating the second paragraph (57) (relating to serious drug felony) and paragraph (58) as paragraphs (58) and (59), respectively; (B) by moving the margin of paragraph (57) 2 ems to the left; (C) by moving the margins of paragraphs (58) and (59), as redesignated, 2 ems to the left; and (D) by adding at the end the following: (60) (A) The term xylazine means the substance xylazine as well as its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible. (B) Except as provided in subparagraph (E), such term does not include a substance described in subparagraph (A) to the extent— (i) such substance is an animal drug that has been approved by the Secretary of Health and Human Services under section 512 of the Federal Food, Drug, and Cosmetic Act and such substance’s use or intended use conforms to the approved application, including the manufacturing, importation, holding, or distribution for such use